Loading clinical trials...

RECRUITING

RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

A Real-world Study of Adjuvant Radiotherapy in High Recurrence Risk Locally Advanced Thyroid Cancer

NCT06524167•Fudan University

Summary

This study is a real-world study to observe the role of adjuvant radiotherapy in locally advanced recurrent high-risk thyroid cancer. The study included thyroid cancer that requires adjuvant radiotherapy to increase local control rate, excluding undifferentiated cancer. Local-regional recurrence free survival is the primary endpoint of the study.

Eligibility

Age

14 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients voluntarily join this study and sign an informed consent form;
•Age: ≥ 14 years old,\<80 years old, male or female not limited;
•Thyroid cancer diagnosed by histopathology, including differentiated thyroid cancer, medullary carcinoma, poorly differentiated carcinoma, etc;
•High risk of local late recurrence, meeting any of the following criteria:
•1. The surgery did not achieve R0 resection;
•2. After neoadjuvant therapy;
•3. Pathological types with poor prognosis, such as poorly differentiated cancer, CASTLE, etc;
•4. Thyroid cancer with obvious extracapsular invasion, invading important structures such as the esophagus, trachea, and recurrent laryngeal nerve, requiring adjuvant radiotherapy;
•5. For patients with distant metastasis, researchers need to determine the value of local treatment;
•The main organ functions are normal;
+1 more criteria

Exclusion Criteria

•Untreated thyroid cancer or thyroid cancer that has only undergone surgical biopsy;
•Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group;
•Previously received radiation therapy for the head and neck area;
•Pregnant or lactating women;
•There are other physical illnesses that affect patients' ability to receive standard treatment;
•According to the researcher's judgment, there may be other factors that could force the subject to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data;
•Individuals with claustrophobia who are unable to undergo radiation therapy;
•Other patients deemed unsuitable for inclusion by the treating physician.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, China

Key Dates

Start Date

July 2, 2024

Primary Completion Date

June 30, 2031

Completion Date

June 30, 2031

Last Updated

February 27, 2026

Enrollment

ESTIMATED participants

Conditions

Thyroid Cancer

Interventions

adjuvant radiotherapy

RADIATION

Contacts

Naisi Huang

CONTACT

86-021-64175590 huangnsisi@fduan.edu.cn

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

NCT06316895

Papillary Thyroid Cancer

View study

RECRUITINGPHASE2

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

NCT07092514

Thyroid CancerCancer of the Thyroid

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

Inclusion Criteria

Exclusion Criteria

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

Natural History Study of Children and Adults With Medullary Thyroid Cancer

Irreversible Electroporation for Recurrent or Metastatic Cervical Lymph Node Metastases From Thyroid Cancer: A Prospective Multicenter Single-Arm Study